gemcitabine,durvalumab,cisplatin,tremelimumab
astrazeneca
['immuchec', 'improve ', 'bladder', 'cisplatin', 'durva', 'tremelimumab', 'gemcitabine']
immuchec trial in na ve cholangio-/gallbladder carcinoma adding io (durvalumab +/- tremelimumab) to chemo (gemcitabine/cisplatin) did not improve efficacy subgroup with dominant pd-1 in immune cells seems to benefit more from the combo #esmo22 
Scientific Communication Manager | Passionate about molecular oncology, clinical and translational research | Photo and music enthusiast | Tweets are mine